1. Articles in category: Information

    1-24 of 232 1 2 3 4 5 6 7 8 9 10 »
    1. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    2. When good immune cells turn bad

      When good immune cells turn bad

      Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have identified new findings about an immune cell - called a tumor-associated macrophage - that promotes cancer instead of fighting it. They have identified the molecular pathway, known as STAT3, as the mechanism the immune cell uses to foster neuroblastoma, a pediatric cancer, and have demonstrated use of a clinically available agent, ruxolitinib, to block the pathway.

      Read Full Article
    3. Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number.

      Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number.

      Oncol Lett. 2017 Sep;14(3):3363-3370

      Authors: Gnanamony M, Antony R, Fernández KS, Jaime L, Lin J, Joseph PA, Gondi CS

      Abstract Neuroblastoma accounts for >15% of cancer-associated mortalities of children in the USA. Despite aggressive treatment regimens, the long-term survival for these children remains <40%.

      Read Full Article
      Mentions: Treatment
    4. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Bioorg Med Chem Lett. 2017 Sep 09;:

      Authors: Takahashi N, Koyama S, Hasegawa S, Yamasaki M, Imai M

      Abstract Neuroblastoma is an aggressive and drug-resistant refractory cancer.

      Read Full Article
      Mentions: Refractory
    5. Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Nat Commun. 2017 Sep 18;8(1):569

      Authors: Chang X, Zhao Y, Hou C, Glessner J, McDaniel L, Diamond MA, Thomas K, Li J, Wei Z, Liu Y, Guo Y, Mentch FD, Qiu H, Kim C, Evans P, Vaksman Z, Diskin SJ, Attiyeh EF, Sleiman P, Maris JM, Hakonarson H

      Read Full Article
      Mentions: MYCN
    6. Patient-derived xenografts as preclinical neuroblastoma models.

      Patient-derived xenografts as preclinical neuroblastoma models.

      Cell Tissue Res. 2017 Sep 19;:

      Authors: Braekeveldt N, Bexell D

      Abstract The prognosis for children with high-risk neuroblastoma is often poor and survivors can suffer from severe side effects. Predictive preclinical models and novel therapeutic strategies for high-risk disease are therefore a clinical imperative.

      Read Full Article
      Mentions: Side Effects
    7. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    8. Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.

      Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Sep 08;:

      Authors: Whittle SB, Punia JN, López-Terrada D, Gaikwad A, Hampton OA, Heczey A

      Abstract Neuroblastoma is the most common extracranial malignancy of childhood.

      Read Full Article
      Mentions: Treatment
    9. When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

      When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

      Cancer Cell. 2017 Sep 11;32(3):273-275

      Authors: Liu Z, Thiele CJ

      Abstract LMO1 is a high-risk neuroblastoma susceptibility gene, but how LMO1 cooperates with MYCN in neuroblastoma tumorigenesis is unclear. In this issue of Cancer Cell, Zhu et al. develop a novel zebrafish model that elucidates a mechanism by which LMO1 and MYCN synergistically initiate neuroblastoma and contribute to metastatic disease progression.

      Read Full Article
      Mentions: MYCN Tumorigenesis
    10. Does Health Insurance Status Affect Childhood Cancer Survival?

      Does Health Insurance Status Affect Childhood Cancer Survival?

      Privately insured children and those with Medicaid at the time of a cancer diagnosis experience largely similar survival trends, with slight evidence for an increased risk of cancer death in children who were uninsured at diagnosis, finds a new study from the Brown School at Washington University in St. Louis.

      Read Full Article
    11. Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.

      Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.

      J Nucl Med. 2017 Sep 08;:

      Authors: Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK

      Read Full Article
      Mentions: Staging SIOPEN COG
    12. Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jan;39(1):e33-e35

      Authors: Cash T, Alazraki A, Qayed M, Katzenstein HM

      Abstract Patients with high-risk neuroblastoma remain a therapeutic challenge with significant numbers of patients failing to respond sufficiently to initial therapy. These patients with poor response to induction are considered as ultra high-risk and are in need of novel treatment strategies.

      Read Full Article
      Mentions: Treatment
    13. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

      Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

      Cochrane Database Syst Rev. 2017 Aug 25;8:CD010685

      Authors: Peinemann F, van Dalen EC, Enk H, Berthold F

      Abstract BACKGROUND: Neuroblastoma is a rare malignant disease and mainly affects infants and very young children. The tumours mainly develop in the adrenal medullary tissue, with an abdominal mass as the most common presentation.

      Read Full Article
      Mentions: INRG
    14. Case report: value of gene expression profiling in the diagnosis of atypical neuroblastoma.

      Case report: value of gene expression profiling in the diagnosis of atypical neuroblastoma.

      BMC Res Notes. 2017 Aug 17;10(1):413

      Authors: Harttrampf AC, Chen Q, Jüttner E, Geiger J, Vansant G, Khan J, Kontny U

      Abstract BACKGROUND: Nephroblastoma and neuroblastoma belong to the most common abdominal malignancies in childhood.

      Read Full Article
      Mentions: GPOH Imaging MYCN
    15. Signs and symptoms of rheumatic diseases as first manifestation of pediatric cancer: diagnosis and prognosis implications.

      Signs and symptoms of rheumatic diseases as first manifestation of pediatric cancer: diagnosis and prognosis implications.

      Rev Bras Reumatol Engl Ed. 2017 Jul - Aug;57(4):330-337

      Authors: Fonseca MB, Gomes FHR, Valera ET, Pileggi GS, Gonfiantini PB, Gonfiantini MB, Ferriani VPL, Carvalho LM

      Read Full Article
    16. Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on (123)I-MIBG SPECT predict the outcome?

      Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on (123)I-MIBG SPECT predict the outcome?

      Eur J Nucl Med Mol Imaging. 2017 Aug 14;:

      Authors: Rogasch JMM, Hundsdoerfer P, Furth C, Wedel F, Hofheinz F, Krüger PC, Lode H, Brenner W, Eggert A, Amthauer H, Schatka I

      Read Full Article
      Mentions: Imaging MYCN MIBG
    17. Anti-GD2 immunotherapy for neuroblastomas.

      Anti-GD2 immunotherapy for neuroblastomas.

      Expert Rev Anticancer Ther. 2017 Aug 07;:

      Authors: Sait S, Modak SI

      Abstract INTRODUCTION: Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving survival and quality of life by reducing exposure to cytotoxic agents.

      Read Full Article
    18. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.

      Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.

      BMC Cancer. 2017 Aug 04;17(1):520

      Authors: Fischer J, Pohl A, Volland R, Hero B, Dübbers M, Cernaianu G, Berthold F, von Schweinitz D, Simon T

      Read Full Article
      Mentions: INRG Imaging MYCN
    19. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

      Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature.

      Read Full Article
    20. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2{alpha} to tumor suppression [Medical Sciences]

      Neuroblastoma is a pediatric cancer characterized by variable outcomes ranging from spontaneous regression to life-threatening progression. High-risk neuroblastoma patients receive myeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differentiation treatment. However, the overall survival remains low; hence, there is an urgent need for alternative therapeutic approaches. One feature...

      Read Full Article
    21. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Proc Natl Acad Sci U S A. 2017 Jul 10;:

      Authors: Westerlund I, Shi Y, Toskas K, Fell SM, Li S, Surova O, Södersten E, Kogner P, Nyman U, Schlisio S, Holmberg J

      Read Full Article
      Mentions: Treatment MYCN
    1-24 of 232 1 2 3 4 5 6 7 8 9 10 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) SIOPEN
    2. (1 articles) COG
  4. Researches in the News

    1. (3 articles) MYCN
    2. (1 articles) Antibody
    3. (1 articles) Tumorigenesis
  5. General Informations in the News

    1. (4 articles) Treatment
    2. (1 articles) Staging
  6. Treatments in the News

    1. (1 articles) Side Effects
    2. (1 articles) Refractory
    3. (1 articles) Stem Cell Transplant